Valentis, Progenitor, Stanford University deal

MBIO acquired rights to Progenitor’s del-1 gene and protein. Del-1 is an extracellular matrix protein involved in angiogenesis that MBIO said may be useful cardiovascular diseases, or, in a mutant form, for inhibition of angiogenesis to treat cancer. Progenitor will receive a one-time cash payment and MBIO will assume milestone and royalty obligations to Vanderbilt University (Nashville, Tenn.) under the university’s previous deal with Progenitor (see BioCentury, July 24, 1995). ...